TY - JOUR
T1 - Proteomic Signature of Mesenchymal Stromal Cell-Derived Small Extracellular Vesicles
AU - van Balkom, Bas W.M.
AU - Gremmels, Hendrik
AU - Giebel, Bernd
AU - Lim, Sai Kiang
N1 - Funding Information:
The authors would like to thank Dr. Alfonso Eirin, Division of Nephrology & Hypertension, Mayo Clinic College of Medicine for providing detailed proteomic datasets, and Dr. Mario Gimona, Spinal Cord Injury & Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medizinische Privatuniversität, for critical reading of the manuscript.
Publisher Copyright:
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Small extracellular vesicles (EVs) are 50–200 nm vesicles secreted by most cells. They are considered as mediators of intercellular communication, and EVs from specific cell types, in particular mesenchymal stem/stromal cells (MSCs), offer powerful therapeutic potential, and can provide a novel therapeutic strategy. They appear promising and safe (as EVs are non-self-replicating), and eventually MSC-derived EVs (MSC-EVs) may be developed to standardized, off-the-shelf allogeneic regenerative and immunomodulatory therapeutics. Promising pre-clinical data have been achieved using MSCs from different sources as EV-producing cells. Similarly, a variety EV isolation and characterization methods have been applied. Interestingly, MSC-EVs obtained from different sources and prepared with different methods show in vitro and in vivo therapeutic effects, indicating that isolated EVs share a common potential. Here, well-characterized and controlled, publicly available proteome profiles of MSC-EVs are compared to identify a common MSC-EV protein signature that might be coupled to the MSC-EVs’ common therapeutic potential. This protein signature may be helpful in developing MSC-EV quality control platforms required to confirm the identity and test for the purity of potential therapeutic MSC-EVs.
AB - Small extracellular vesicles (EVs) are 50–200 nm vesicles secreted by most cells. They are considered as mediators of intercellular communication, and EVs from specific cell types, in particular mesenchymal stem/stromal cells (MSCs), offer powerful therapeutic potential, and can provide a novel therapeutic strategy. They appear promising and safe (as EVs are non-self-replicating), and eventually MSC-derived EVs (MSC-EVs) may be developed to standardized, off-the-shelf allogeneic regenerative and immunomodulatory therapeutics. Promising pre-clinical data have been achieved using MSCs from different sources as EV-producing cells. Similarly, a variety EV isolation and characterization methods have been applied. Interestingly, MSC-EVs obtained from different sources and prepared with different methods show in vitro and in vivo therapeutic effects, indicating that isolated EVs share a common potential. Here, well-characterized and controlled, publicly available proteome profiles of MSC-EVs are compared to identify a common MSC-EV protein signature that might be coupled to the MSC-EVs’ common therapeutic potential. This protein signature may be helpful in developing MSC-EV quality control platforms required to confirm the identity and test for the purity of potential therapeutic MSC-EVs.
KW - cell therapy
KW - clinical translation
KW - exosomes
KW - standardization
KW - stem cells
UR - http://www.scopus.com/inward/record.url?scp=85059562302&partnerID=8YFLogxK
U2 - 10.1002/pmic.201800163
DO - 10.1002/pmic.201800163
M3 - Article
C2 - 30467989
AN - SCOPUS:85059562302
SN - 1615-9853
VL - 19
JO - Proteomics
JF - Proteomics
IS - 1-2
M1 - 1800163
ER -